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Abstract
BACKGROUND: The natural history of hepatitis B virus (HBV) is complex and influenced by the level of viral
replication and host factors. The hepatoprotective role of high density lipoproteins (HDL) and adiponectin as host
factors on HBV persistence is less well understood.
METHODS: To investigate correlation between HBV DNA level with clinical parameters in patients with chronic
hepatitis B, 92 male subjects with HBV infection without any risk factors for diabetes were enrolled in this study.
Age and BMI of the study population were matched and HBV DNA, ALT, tumor necrosis factor alpha (TNF-a),
adiponectin and lipid levels was measured.
RESULTS: Serum HBV DNA correlated inversely with serum HDL level (r = -0.23; P = 0.014). The median of log
copies/ml for HBV DNA (3.67) was considered as cut off point. Patients with HBV DNA level higher than cut off
point had lower adiponectin (8.7 ± 5.3 vs 10.7 ± 4.9 μg/ml p = 0.05). Also, adiponectin had a negative correlation
with TNF-a (r = -0.21, P = 0.04) and positive correlations with HDL (r = 0.18, P = 0.043).Multivariate regression
models show that serum HDL level is an independed factor to predict serum HBV DNA.
CONCLUSION: Our findings showed that higher HBV DNA levels are associated with lower HDL and adiponectin
but induced TNF-alpha values.
Introduction
The broad outcomes of hepatitis B virus (HBV) infec-
tion can be divided into acute infection and chronic
hepatitis [1]. The ongoing replication of HBV in
chronic hepatitis induce oxidative stress and associated
with liver inflammation, which over the course of years
increases risk of fibrosis, cirrhosis, and liver cancer
[2,3]. Factors which determine viral replication and
outcome of infection are not fully understood,
although host factors are known to play a major role
in this regard [4]. Among these factors, HDL, with sev-
eral biological properties, including anti oxidative and
anti inflammatory activities has a potential role to be a
part of nonspecific immunity [5,6]. Adiponectin also
attenuates inflammation, oxidative stress, and pro-
inflammatory cytokine production [7].
The anti-inflammatory function of HDL involves induc-
tion transforming growth factor b which might function as
an important mediator of the anti-inflammatory activity
[8]. In chronic hepatitis B patients, serum HDL concentra-
tion inversely correlates with excess release of pro-inflam-
matory response and progressive liver disease [9,10].
Adiponectin, an adipose tissue-specific protein puts multi-
ple beneficial effects on tissue and vascular physiology. At
physiological concentrations, adiponectin suppresses TNF-
a induced NF-b activation and blocks TNF-a release in
endothelial cells [7]. It also ameliorates liver fibrosis via
suppression of activated hepatic stellate cells function, and
might slow down progression of hepatocarcinogenesis via
suppression of oxidative stress [11]. In addition, adiponec-
tin activates peroxisome proliferator-activated receptor-a
(PPAR-a) to up-regulates the hepatic expression of
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increased hepatic HDL secretion [12,13]. Animal models
revealed the hepatoprotective action of adiponectin [14]. It
was shown that adiponectin exert its hepatoprotective
function by increasing activation of mitochondrial fatty
acids b-oxidation and thus reductions of circulation free
fatty acid [13,15].
HDL and adiponectin share common metabolic path-
ways, however, their role in liver diseases associated
with chronic hepatitis B infection is not well under-
stood. To further investigate association of HDL and
adiponectin with HBV replication rate and therefore
introducing a possible strategy for treating patients with
chronic hepatitis B, we examined serum HBV DNA
level with regard to serum HDL concentration as well as
adiponectin and proposing their beneficial function in
treating chronic hepatitis B.
Materials and methods
Patients
Sera from 92 male adult carriers, positive for HBsAg
and HBV DNA and negative for HBeAg as well as HCV,
HDV, and HIV antibodies referring to a tertiary univer-
sity-based referral center between September 2006 and
November 2008 for regularly follow up were collected.
None of the patients had evidence of cirrhosis and/or
hepatocellular carcinoma. There was no clinical or para-
clinical evidence of diabetes mellitus based on criteria
defined by World Health Organization [16]. Both nor-
mal and elevated ALTs were included in the study.
Patients had no history of treatment for HBV prior to
the study and they also had no alcohol consumption.
Study protocol was approved by the Ethics Committee
of Tehran University of Medical Sciences (TUMS).
Informed consent was obtained from all participant.
Clinical and Laboratory Assessments
Following to an overnight fasting (12h) serum ALT,
total cholesterol, triglycerides, high-density lipoprotein
(HDL), fasting blood sugar (FBS), Albumin and Bilirubin
were measured with commercial kits using a Hitachi
7250 special autoanalyzer (Hitachi, Tokyo, Japan). The
body mass index (BMI) was calculated by the formula:
weight (kg)/height (m
2).
Determination of Serum Adiponectin Level and TNF-a
Both serum adiponectin and TNF-a were measured
using enzyme immunoassay Orgenium (Vantaa, Finland)
for adiponectin and Bender Medsystems (Vienna, Aus-
tria) for TNF-a.
Virological Assessment
HBs- and HBe- Antigens were tested using commer-
cially available enzyme-linked immunosorbent assay kits
from RADIM (Italy). HBV DNA was extracted from 200
μl of serum using QIAamp DNA Blood Mini Kit (QIA-
GEN USA) according to the manufacturer’s instructions.
HBV DNA was then quantified in the Light-Cycler
(Roche) using the RealART™ HBV LC PCR (QIAGEN,
Hilden, Germany) according to the manufacturer’s
instructions. The linear range of this assay was 10
2-10
9
copies/ml.
Statistical Analysis
Results were expressed as mean ± standard deviation.
Relations between continuous variables were tested
using Spearman’s rank correlation coefficients, Pear-
son correlation coefficients and multivariate linear
regression models. Adjustment on age, ALT and BMI
was performed using multivariate regression models.
Kolmogrov-Smirno test was used to test the normality
in continues variables (Ramlu-Hansen 1983). When
normal distribution assumption was not met for some
variables, the square root transformation was used to
change continues variables to normal distribution.
L o gc o p i e s / m lH B VD N Aw a sc o n s i d e r e da sac o n -
tinues variable in multivariate regression models and
when it was considered as a dichotomous variable
(less than median and more than median) logistic
regression models was used to check association
between HBV DNA and other variables. Mean differ-
ences were tested by Student’s t-test. To find non-
linear association between HBV DNA and HDL with
adiponectin in scatter plots, Epanechnikov kernel
smooting was used. Analyses were done using STATA
ver. 10. P-value less than .05 was considered
significant.
Results
Characteristics and Clinical Parameters of study
population
Demographic and biochemical characteristics of 92 con-
secutive middle-aged and normal weight male subjects
with chronic hepatitis B are presented in Table 1. Mean
of serum HBV DNA, HDL and ALT level were 3.7 ± 0.9
log copies/ml, 49 ± 11mg/dl and 48 ± 51 IU/l and for
serum adiponectin and TNF-alpha were 9.7 ± 5.2 ng/ml
and 10.6 ± 3.6 ng/L respectively.
Biochemical Evaluation in Patients with Chronic Hepatitis B
Serum HBV DNA (log copies/ml) associated with ALT
level (r = 0.3, P = 0.001). A negative correlation was
noted between HBV DNA and serum HDL (r = -0.24,
P = 0.014). The same correlation was found between
adiponectin with TNF-alpha and triglyceride (r = -0.21,
P = 0.04, r = -0.21, P = 0.037). In contrast, serum adipo-
nectin showed a positive correlation with serum HDL
levels (r = 0.21, P = 0.05). There was no statistically
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nectin with FBS, Albumin, Bilirubin, BMI, age, ALT and
cholesterol.
Association of Serum HDL and Adiponectin with HBV
DNA
Analysis with median 3.67 for log copies/ml HBV DNA
-set as a cut off point- showed that patients with HBV
DNA higher than this level had higher levels of ALT (61 ±
65 vs 36 ± 26 p = 0.02), but lower HDL and adiponectin
(47 ± 10 vs 52 ± 12 p = 0.04 and 8.7 ± 5.3 vs 10.7 ± 4.9
p = 0.05 respectively) (Table 2). When Log HBV DNA
was considered as a continuous variable in a multivariate
regression model we estimate equation:
Log HBV DNA= 4.4 -0.029 adiponectin -0.014 HDL
+0.006 ALT
This regression equation shows that with considering
adjustment on ALT variable, increasing HDL and adipo-
nectin variables decrease Log HBV DNA.
TNF-a was significantly elevated in patients with HBV
DNA levels more than median compared with those in
HBV DNA levels less than median (11.5 ± 4.2 vs 9.7 ±
2.7 p = 0.017).
We found that 31% of patients with HBV DNA higher
than median had serum HDL less than 40 mg/dl, while
15% of patients with HBV DNA lower than median had
serum HDL less than 40 mg/dl. Although the Chi-
squared P value was 0.06, but it was identified that the
number of patients with HDL less than 40 mg/dl and
HBV DNA higher than median is approximately 2 times
more compared to patients who have HDL less than
40 mg/dl and HBV DNA lower than median.
In a multivariate regression model with depended
variable Log HBV DNA and independed variables serum
HDL, age, and BMI ,correlation between Log HBV and
serum HDL was statistically significant (P = 0.036. b =
-0.018). Coefficient of regression analysis showed an
increased unit of serum HDL accompanied with 1.8 per-
cent reduction in log HBV DNA. When adjustment was
done on ALT in the multivariate regression model, the
association between Log HBV DNA and serum HDL
was significant ( P = 0.046, b = -0.016).
Epanechnikov kernel smoothing showed that, patients
with serum HDL less than 40, had not a significant
association with HBV DNA (r = 0.251,P = 0.76,n = 21)
but in patients with serum HDL more than 40 this asso-
ciation was negative (r = -0.247,P = 0.038,n = 71) (Fig-
ure 1 and 2). Therefore, HBV DNA considered as a
continuous variable in linear regression and a dichoto-
mous variable in logistic regression (less than 3.67 and
more than 3.67), however, the result of two methods
was approximately same.
According to Epanechnikov kernel smoothing in figure
3 we choose 16 as a cut off point for adiponectin. Eighty
patients with adiponectin less than 16, had a negative
association with HBV DNA (r = -0.22, P = 0.049, n =
80). Regression equation shows that each unit increases
in adiponectin accompanied with 0.05 unit decreases in
log HBV DNA (t = 2.004, P = .049).
There were a few cases that had high levels of adipo-
nectin, after omitting these cases there was negative cor-
relation between Log HBV DNA and serum HDL (r =
-0.27,P = 0.01 n = 88) and adiponectin (r = -0.17,P =
0.11, n = 88) figure 4 shows this relationship.
Discussion
Development of cirrhosis and HCC has been attributed
to the higher replication index of HBV [17-19]. Thus
serum HBV DNA could play important role for moni-
toring outcome of chronic hepatitis B infection which in
part seems to be affected by host factors. The key find-
ing of our investigation was significant negative correla-
tion between HDL and HBV DNA. Moreover we
Table 1 Clinical and biochemical characteristics of
patients
Characteristics of patients (n = 92) Mean ± SD
Age(Years) 39 ± 10
BMI (kg/m2) 25.5 ± 1.2
FBS (mg/dl) 85 ± 13
Albumin (g/dl) 4.3 ± 0.5
Bilirubin total (mg%) 0.6 ± 0.3
ALT (IU/l) 48 ± 51
Cholesterol (mg/dl) 168 ± 33
Triglyceride (mg/dl) 138 ± 42
HDL (mg/dl) 49 ± 11
Adiponectin (ng/ml) 9.7 ± 5.2
TNF-alpha (ng/L) 10.6 ± 3.6
HBV DNA (log copies/ml) 3.7 ± 0.9
Table 2 Association of clinical findings of chronic
hepatitis B with HBV DNA level higher than median log
copies/ml or lower than median (3.67 log copies/ml)
Clinical factor HBV DNA <
median *
HBV DNA >
median *
P
value
Age (Years) 41 ± 10 38 ± 11 0.12
BMI (kg/m2) 25.4 ± 1.1 25.6 ± 1.2 0.47
FBS (mg/dl) 83 ± 14 86 ± 8 0.2
Albumin (g/dl) 4.3 ± 0.5 4.2 ± 0.5 0.7
Bilirubin total (mg%) 0.5 ± 0.2 0.6 ± 0.2 0.7
ALT (IU/l) 36 ± 26 61 ± 65 0.021
Cholesterol (mg/dl) 172 ± 31 164 ± 34 0.27
Triglyceride (mg/dl) 136 ± 44 140 ± 39 0.62
HDL (mg/dl) 52 ± 12 47 ± 10 0.04
Adiponectin (μg/ml) 10.7 ± 4.9 8.7 ± 5.3 0.057
TNF-a (ng/L) 9.7 ± 2.7 11.5 ± 4.2 0.017
*Mean ± SD
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HBV DNA and adiponectin in a concentration less than
16 μg/ml. These associations indicating that HDL can
itself reduce viral infection by potent anti-infectious
activity [5]. HDL was shown to be part of nonspecific
innate immunity. Changes including altered HDL con-
tent and HDL apolipoprotein composition might redir-
ect cholesterol from the liver to immune cells during
infection [5,20].
Regarding to viral infectious diseases; influenza infec-
tion accompanies with decreased levels of HDL [21]. It
has also been reported that HIV-1 RNA viral load corre-
lates with low HDL-Cholesterol levels [22]. In addition
high levels of HDL-cholesterol associate with a better
viral response in treated HIV patients [23]. A study car-
ried out in Asian chronic hepatitis C patients, demon-
s t r a t e dt h a tH D Lh a das i g n i f i c a n te f f e c to ne a r l yv i r a l
load decline [24]. Finally most other studies have
observed decreased levels of high-density lipoprotein-
cholesterol in chronic hepatitis B virus infection [10,25].
HDL restores the hepatice endothelial nitric oxide
synthase (eNOS) activity which is down regulated in cir-
rhotic patients. Hence, Thabut et al, showed limited
anti-infectious activity in cirrhotic rats with decreased
circulating HDL [26]. Herein, we demonstrate the pro-
tective effects of HDL to keep lower HBV DNA. It is
probable that HDL is a component of the innate
immune system that can limit infections [27]. The
Figure 1 Scatter plot of HDL (mg/dl) and HBV DNA (log copies/
ml) with Epanechnikov kernel smoothing line.
Figure 2 Scatter plot of HDL (mg/dl) and HBV DNA (log copies/
ml) with Epanechnikov kernel smoothing line in HDL less than
40 (star mark) and HDL more than 40 (cycle marks).
Figure 3 Scatter plot of adiponectin (μg/ml) and HBV DNA (log
copies/ml) with Epanechnikov kernel smoothing line.
Figure 4 Scatter plot of adiponectin (μg/ml) and HBV DNA (log
copies/ml) with Epanechnikov kernel smoothing line when
patient’s adiponectin with adiponectin more than 20 were
omitted.
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neutrophils has been studied in vitro [ 2 8 ] ,h e r ew ep r o -
pose in vivo, in addition to macrophages, HBV might be
transferred to HDL and endocytosed within neutrophils.
As noted earlier, Adiponectin likely promotes HDL
formation on multiple fronts [13]. We have now shown
that adiponectin, independent from common metabolic
risk factors contributes inversely with regards to HBV
DNA. The positive relationship of adiponectin with the
metabolic profile in adults has been less studied in
chronic hepatitis B patients. Hui and co-worker reported
that serum adiponectin may have a role in fibrosis pro-
gression in CHB infection [29]. In contrast another
study has suggested that increased serum adiponectin in
hepatic inflammatory activity which is an antagonizing
TNF-a, may be a secondary to the response to hepatic
injury in chronic hepatitis B [9]. Cytokines including
TNF-a, are mediators of inflammation and appears to
have a direct effect to inhibit apolipoproteins production
by hepatocytes [30].
In summary, while the association between log HBV-
DNA and serum HDL was not linear, patients with
serum HDL more than 40 mg/dl showed a negative cor-
relation with HBV DNA. In this study we adjusted the
population under study for ag e ,s e x ,B M I ,a n dr i s kf a c -
tors for diabetes which inversely correlate with serum
HDL and adiponectin level [31] in order to obtain more
reliable results when assessing the association of vari-
ables with the amount of HBV DNA. Thus our investi-
gation suggests that serum HDL concentration could
play inhibitory function for hepatitis B viral replication.
In addition, adiponectin may also participate in the
reduction of viral replication in CHB patients through
activation of HDL production. However it should be
noted that data regarding to association between serum
adiponectin with the circulating HBV DNA level is still
rather conflicting. Therefore, this association should be
studied in prospective, carefully designed group con-
trolled studies including large cohorts of patients with
meticulous consideration of metabolic and other poten-
tial confounding factors.
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